BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 21683980)

  • 1. Low activated leukocyte cell adhesion molecule expression is associated with advanced tumor stage and early prostate-specific antigen relapse in prostate cancer.
    Minner S; Kraetzig F; Tachezy M; Kilic E; Graefen M; Wilczak W; Bokemeyer C; Huland H; Sauter G; Schlomm T
    Hum Pathol; 2011 Dec; 42(12):1946-52. PubMed ID: 21683980
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Biologic role of activated leukocyte cell adhesion molecule overexpression in breast cancer cell lines and clinical tumor tissue.
    Hein S; Müller V; Köhler N; Wikman H; Krenkel S; Streichert T; Schweizer M; Riethdorf S; Assmann V; Ihnen M; Beck K; Issa R; Jänicke F; Pantel K; Milde-Langosch K
    Breast Cancer Res Treat; 2011 Sep; 129(2):347-60. PubMed ID: 20972617
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunological microenvironment in prostate cancer: high mast cell densities are associated with favorable tumor characteristics and good prognosis.
    Fleischmann A; Schlomm T; Köllermann J; Sekulic N; Huland H; Mirlacher M; Sauter G; Simon R; Erbersdobler A
    Prostate; 2009 Jun; 69(9):976-81. PubMed ID: 19274666
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Subcellular localization of activated leukocyte cell adhesion molecule is a molecular predictor of survival in ovarian carcinoma patients.
    Mezzanzanica D; Fabbi M; Bagnoli M; Staurengo S; Losa M; Balladore E; Alberti P; Lusa L; Ditto A; Ferrini S; Pierotti MA; Barbareschi M; Pilotti S; Canevari S
    Clin Cancer Res; 2008 Mar; 14(6):1726-33. PubMed ID: 18347173
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Distinct subcellular expression patterns of neutral endopeptidase (CD10) in prostate cancer predict diverging clinical courses in surgically treated patients.
    Fleischmann A; Schlomm T; Huland H; Köllermann J; Simon P; Mirlacher M; Salomon G; Chun FH; Steuber T; Simon R; Sauter G; Graefen M; Erbersdobler A
    Clin Cancer Res; 2008 Dec; 14(23):7838-42. PubMed ID: 19047112
    [TBL] [Abstract][Full Text] [Related]  

  • 6. ALCAM (CD166) expression as novel prognostic biomarker for pancreatic neuroendocrine tumor patients.
    Tachezy M; Zander H; Marx AH; Gebauer F; Rawnaq T; Kaifi JT; Sauter G; Izbicki JR; Bockhorn M
    J Surg Res; 2011 Oct; 170(2):226-32. PubMed ID: 21816425
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Activated leukocyte cell adhesion molecule (CD166)--its prognostic power for colorectal cancer patients.
    Tachezy M; Zander H; Gebauer F; Marx A; Kaifi JT; Izbicki JR; Bockhorn M
    J Surg Res; 2012 Sep; 177(1):e15-20. PubMed ID: 22482754
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Heat shock protein expression independently predicts clinical outcome in prostate cancer.
    Cornford PA; Dodson AR; Parsons KF; Desmond AD; Woolfenden A; Fordham M; Neoptolemos JP; Ke Y; Foster CS
    Cancer Res; 2000 Dec; 60(24):7099-105. PubMed ID: 11156417
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of positive surgical margins on prostate-specific antigen failure after radical prostatectomy in adjuvant treatment-naïve patients.
    Ploussard G; Agamy MA; Alenda O; Allory Y; Mouracade P; Vordos D; Hoznek A; Abbou CC; de la Taille A; Salomon L
    BJU Int; 2011 Jun; 107(11):1748-54. PubMed ID: 20883488
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognostic value of cell cycle proteins p27(kip1) and MIB-1, and the cell adhesion protein CD44s in surgically treated patients with prostate cancer.
    Vis AN; Noordzij MA; Fitoz K; Wildhagen MF; Schröder FH; van der Kwast TH
    J Urol; 2000 Dec; 164(6):2156-61. PubMed ID: 11061947
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Low level HER2 overexpression is associated with rapid tumor cell proliferation and poor prognosis in prostate cancer.
    Minner S; Jessen B; Stiedenroth L; Burandt E; Köllermann J; Mirlacher M; Erbersdobler A; Eichelberg C; Fisch M; Brümmendorf TH; Bokemeyer C; Simon R; Steuber T; Graefen M; Huland H; Sauter G; Schlomm T
    Clin Cancer Res; 2010 Mar; 16(5):1553-60. PubMed ID: 20179235
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Importance of tumor location in patients with high preoperative prostate specific antigen levels (greater than 20 ng/ml) treated with radical prostatectomy.
    Magheli A; Rais-Bahrami S; Peck HJ; Walsh PC; Epstein JI; Trock BJ; Gonzalgo ML
    J Urol; 2007 Oct; 178(4 Pt 1):1311-5. PubMed ID: 17698095
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Decreased RECK expression indicating proteolytic imbalance in prostate cancer is associated with higher tumor aggressiveness and risk of prostate-specific antigen relapse after radical prostatectomy.
    Rabien A; Burkhardt M; Jung M; Fritzsche F; Ringsdorf M; Schicktanz H; Loening SA; Kristiansen G; Jung K
    Eur Urol; 2007 May; 51(5):1259-66. PubMed ID: 16806661
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Increased CD59 protein expression predicts a PSA relapse in patients after radical prostatectomy.
    Xu C; Jung M; Burkhardt M; Stephan C; Schnorr D; Loening S; Jung K; Dietel M; Kristiansen G
    Prostate; 2005 Feb; 62(3):224-32. PubMed ID: 15389793
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Decreased immunostaining for macrophage scavenger receptor is associated with poor prognosis of prostate cancer.
    Takayama H; Nonomura N; Nishimura K; Oka D; Shiba M; Nakai Y; Nakayama M; Tsujimura A; Aozasa K; Okuyama A
    BJU Int; 2009 Feb; 103(4):470-4. PubMed ID: 18778349
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Low p27 expression predicts poor disease-free survival in patients with prostate cancer.
    Yang RM; Naitoh J; Murphy M; Wang HJ; Phillipson J; deKernion JB; Loda M; Reiter RE
    J Urol; 1998 Mar; 159(3):941-5. PubMed ID: 9474188
    [TBL] [Abstract][Full Text] [Related]  

  • 17. External beam radiotherapy versus radical prostatectomy for clinical stage T1-2 prostate cancer: therapeutic implications of stratification by pretreatment PSA levels and biopsy Gleason scores.
    Kupelian P; Katcher J; Levin H; Zippe C; Suh J; Macklis R; Klein E
    Cancer J Sci Am; 1997; 3(2):78-87. PubMed ID: 9099457
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lymphovascular invasion is an independent prognostic factor in prostatic adenocarcinoma.
    Cheng L; Jones TD; Lin H; Eble JN; Zeng G; Carr MD; Koch MO
    J Urol; 2005 Dec; 174(6):2181-5. PubMed ID: 16280760
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Activated leukocyte cell adhesion molecule (CD166): an "inert" cancer stem cell marker for non-small cell lung cancer?
    Tachezy M; Zander H; Wolters-Eisfeld G; Müller J; Wicklein D; Gebauer F; Izbicki JR; Bockhorn M
    Stem Cells; 2014 Jun; 32(6):1429-36. PubMed ID: 24501004
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic significance of p53 nuclear accumulation in localized prostate cancer treated with radical prostatectomy.
    Quinn DI; Henshall SM; Head DR; Golovsky D; Wilson JD; Brenner PC; Turner JJ; Delprado W; Finlayson JF; Stricker PD; Grygiel JJ; Sutherland RL
    Cancer Res; 2000 Mar; 60(6):1585-94. PubMed ID: 10749127
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.